Caitlin A. Finney

Proteomic signatures of APOE ε4 across human tissues and cell types in Alzheimers disease

This study identifies a consistent proteomic signature of APOE ε4 across plasma and CSF, revealing cell-type-specific molecular effects in brain tissues associated with Alzheimer's disease risk.

An integrated atlas of RNA to protein concordance across human tissues and cell types

The paper creates an integrated atlas linking RNA and protein expression across human tissues and cell types, identifying genes that reliably translate RNA into protein.

Patient cerebral organoids capture Alzheimers disease proteomic biomarkers and drug targets

The paper benchmarks proteomic biomarkers and drug targets in patient-derived cerebral organoids against clinical cohorts, finding they detect most candidates and replicate disease changes in a quarter of reproducible markers.

Adding iPSC donor lines does not adequately control for genetic heterogeneity

This paper evaluates the adequacy of using 3-5 iPSC donor lines to control for genetic heterogeneity and finds that these sample sizes are insufficient for reliable detection or estimation of donor-level variance.

APOE ε4 defines a systemic immune endophenotype independent of clinical trajectory in amyotrophic lateral sclerosis

This study identifies an APOE ε4-associated systemic immune proteomic signature in ALS that predicts disease progression independently of clinical features.

Mapping the circulating proteome across neurodegeneration: A harmonized, consortium-scale framework for uncovering molecular pathophysiology

The paper presents a harmonized framework for analyzing large-scale plasma proteomics data across neurodegenerative diseases, identifying disease-specific circulating signatures and biomarkers.

Cerebrospinal fluid proteome profiling using machine learning shows a unique protein signature associated with APOE4 genotype

This study identifies an APOE4-specific cerebrospinal fluid proteome signature using machine learning, independent of Alzheimer's disease diagnosis and associated with increased risk of cognitive impairment.

A Systematic Review of the Neuroprotective Role and Biomarker Potential of GDF15 in Neurodegeneration

This review evaluates GDF15's neuroprotective role and biomarker potential in neurodegeneration and neurotrauma, highlighting its upregulation and therapeutic benefits in preclinical models.

The neuroprotective effects of estrogen and estrogenic compounds in spinal cord injury

This review evaluates estrogen and estrogenic compounds' neuroprotective effects in spinal cord injury, finding they reduce inflammation and improve functional outcomes.

Artificial intelligence-driven meta-analysis of brain gene expression identifies novel gene candidates and a role for mitochondria in Alzheimers Disease

This study uses AI-driven meta-analysis of brain gene expression data to identify novel gene candidates and highlights mitochondrial dysfunction in Alzheimer's disease.

The selective estrogen receptor modulator tamoxifen protects against subtle cognitive decline and early markers of injury twenty-four hours after hippocampal silent infarct

This study shows tamoxifen protects against early cognitive and cellular damage caused by hippocampal silent infarcts in rats within 24 hours.

Hippocampal silent infarct leads to subtle cognitive decline that is associated with inflammation and gliosis at twenty-four hours after injury in a rat model

This study shows that hippocampal silent infarcts in rats cause subtle cognitive decline 24 hours post-injury, linked to inflammation, gliosis, and apoptosis.